SG11202005822PA - Therapeutic agent for nervous system disease - Google Patents

Therapeutic agent for nervous system disease

Info

Publication number
SG11202005822PA
SG11202005822PA SG11202005822PA SG11202005822PA SG11202005822PA SG 11202005822P A SG11202005822P A SG 11202005822PA SG 11202005822P A SG11202005822P A SG 11202005822PA SG 11202005822P A SG11202005822P A SG 11202005822PA SG 11202005822P A SG11202005822P A SG 11202005822PA
Authority
SG
Singapore
Prior art keywords
therapeutic agent
nervous system
system disease
disease
nervous
Prior art date
Application number
SG11202005822PA
Other languages
English (en)
Inventor
Hiroyuki Tanaka
Hideki Yoshikawa
Hideki Mochizuki
Tsuyoshi Murase
Tsutomu Sasaki
Kousuke Baba
Toru Iwahashi
Mitsuru Naiki
Original Assignee
Univ Osaka
Nippon Zoki Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Nippon Zoki Pharmaceutical Co filed Critical Univ Osaka
Publication of SG11202005822PA publication Critical patent/SG11202005822PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SG11202005822PA 2017-12-21 2018-12-20 Therapeutic agent for nervous system disease SG11202005822PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017245133 2017-12-21
JP2018156503 2018-08-23
PCT/JP2018/046945 WO2019124483A1 (ja) 2017-12-21 2018-12-20 神経系疾患治療剤

Publications (1)

Publication Number Publication Date
SG11202005822PA true SG11202005822PA (en) 2020-07-29

Family

ID=66993523

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005822PA SG11202005822PA (en) 2017-12-21 2018-12-20 Therapeutic agent for nervous system disease

Country Status (13)

Country Link
US (3) US11369626B2 (ja)
EP (1) EP3730144A4 (ja)
JP (3) JP6650650B2 (ja)
KR (1) KR20200101948A (ja)
CN (1) CN111511373A (ja)
AU (1) AU2018390261B2 (ja)
CA (1) CA3086220A1 (ja)
IL (1) IL275479A (ja)
RU (1) RU2020123957A (ja)
SG (1) SG11202005822PA (ja)
TW (1) TWI798320B (ja)
WO (1) WO2019124483A1 (ja)
ZA (1) ZA202004433B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6650650B2 (ja) * 2017-12-21 2020-02-19 国立大学法人大阪大学 神経系疾患治療剤
CN112826827A (zh) * 2021-01-24 2021-05-25 华中科技大学同济医学院附属协和医院 甲钴胺在毒物诱导的脊髓变性样疾病中的应用
WO2023004235A1 (en) * 2021-07-23 2023-01-26 University Of Florida Research Foundation, Incorporated Controlling pro-inflammatory macrophage phenotype through biofunctional hydrogel design

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3889844B2 (ja) * 1997-02-10 2007-03-07 龍兒 梶 筋萎縮性側索硬化症治療剤
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
CN1135973C (zh) * 1999-01-18 2004-01-28 倪荣聪 蛋氨酸组合物在制备治疗心、脑血管疾病的药物中的应用
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
WO2002087593A1 (en) * 2001-04-25 2002-11-07 Cobalz Limited A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
US20030018009A1 (en) * 2001-06-20 2003-01-23 Collins Douglas A. Adenosyl-cobalamin fortified compositions
US6951658B1 (en) * 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
US20050032740A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin compositions for the treatment and prevention of vascular disease and dementia
DE102005001479A1 (de) * 2005-01-12 2006-07-20 Synavit Gmbh Mittel, enthaltend Folsäure, Vitamin B6 und Vitamin B12, und dessen Verwendung
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
GB0723972D0 (en) * 2007-12-07 2008-01-23 Queen Mary & Westfield College Use of vitamin B12
KR20110136826A (ko) 2009-03-26 2011-12-21 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규의 인지기능장해 치료제
WO2011043136A1 (ja) 2009-10-08 2011-04-14 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する免疫抑制剤及びその用途
EP2554175B1 (en) 2010-03-26 2018-02-28 Tokushima University Composition for treatment of damaged part
JP5223035B2 (ja) 2010-05-27 2013-06-26 国立大学法人 東京大学 抗炎症薬
WO2012125020A1 (en) 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
CN102631667B (zh) * 2012-04-19 2013-10-02 赵廷宝 促神经再生注射剂及其制备方法
CN102772407B (zh) * 2012-08-01 2014-09-17 岳茂兴 一种促进神经损伤修复的药物组合物及其应用
EP2968117A1 (en) 2013-03-14 2016-01-20 Pharmaceutical Productions Inc. Method of treating vitamin b12 deficiency
US10130657B2 (en) * 2015-02-13 2018-11-20 John C. Hughes Formulation, apparatus, and methods for treatment of brain trauma
CN104688763A (zh) * 2015-03-11 2015-06-10 刘力 包括手性异构化合物的赖肌维药物组合物及其用途
SG11201806797UA (en) * 2016-03-07 2018-09-27 Univ Osaka Sustained drug release sheet for treating nerve injury
CN107595874B (zh) * 2016-07-12 2020-10-30 石药集团恩必普药业有限公司 一种含有丁苯酞的药物组合物及其在制备治疗脑血管病药物中的应用
CN107595875B (zh) * 2016-07-12 2020-10-30 石药集团恩必普药业有限公司 含有丁苯酞的组合物及其在治疗脑血管病药物中的应用
CN106107388A (zh) * 2016-07-31 2016-11-16 合肥远志医药科技开发有限公司 一种淡竹叶菊花植物饮料及其制作方法
JP6650650B2 (ja) * 2017-12-21 2020-02-19 国立大学法人大阪大学 神経系疾患治療剤

Also Published As

Publication number Publication date
WO2019124483A1 (ja) 2019-06-27
CA3086220A1 (en) 2019-06-27
US20220273692A1 (en) 2022-09-01
CN111511373A (zh) 2020-08-07
JP2020075931A (ja) 2020-05-21
TW201929871A (zh) 2019-08-01
AU2018390261B2 (en) 2023-03-16
RU2020123957A (ru) 2022-01-26
JP6763533B2 (ja) 2020-09-30
US11679122B2 (en) 2023-06-20
AU2018390261A1 (en) 2020-08-06
US20210008092A1 (en) 2021-01-14
EP3730144A4 (en) 2021-09-01
KR20200101948A (ko) 2020-08-28
JPWO2019124483A1 (ja) 2019-12-26
ZA202004433B (en) 2022-01-26
US20230302040A1 (en) 2023-09-28
EP3730144A1 (en) 2020-10-28
JP6708869B2 (ja) 2020-06-10
TWI798320B (zh) 2023-04-11
US11369626B2 (en) 2022-06-28
JP2020117529A (ja) 2020-08-06
IL275479A (en) 2020-08-31
JP6650650B2 (ja) 2020-02-19

Similar Documents

Publication Publication Date Title
GB201709456D0 (en) Therapeutic agents
GB201603104D0 (en) Therapeutic agents
ME03454B (me) Terapeutski agensi za neurodegenerativne bolesti
IL263188B (en) Treatment for Parkinson's disease
ZA202004433B (en) Therapeutic agent for nervous system disease
GB201716942D0 (en) Therapeutic compounds
IL281869A (en) Medical factor for neurodegenerative disease
IL273929A (en) Therapeutic agents for neurodegenerative diseases
GB201700553D0 (en) Therapeutic agents
EP3593771C0 (en) SYSTEM FOR NEUROPROTECTIVE THERAPY AGAINST GLAUCOMA
SG11201705915VA (en) Therapeutic agent for ischemic diseases
IL257740A (en) Medicinal compounds for pain and their synthesis
ZA201807944B (en) Treatment for parkinson's disease
GB201712395D0 (en) Therapeutic compounds
GB201712394D0 (en) Therapeutic compounds
GB201712393D0 (en) Therapeutic compounds
GB201712390D0 (en) Therapeutic compounds
GB201712388D0 (en) Therapeutic compounds
GB201712392D0 (en) Therapeutic compounds
HU5050U (hu) Hõterápiás rendszer
GB201702921D0 (en) Therapeutic agent
GB201702052D0 (en) Therapeutic agents
GB201702047D0 (en) Therapeutic agents
GB201701631D0 (en) Therapeutic agents
GB201701570D0 (en) Therapeutic agents